In total, administration of [ATP enhancer] to 65 subjects provides support for its safe use in humans, and that latest study in PD patients found that MDS-UPDRS Part III-Motor Score significantly improved after 57 days of treatment. In addition, we were recently granted a patent in the U.S. for our novel method of enhancing cellular ATP and its use as a drug. On top of the previously issued Japanese patent, that patent affords our company protection in two of the world’s most important drug markets. Finally, additional patent applications have recently been published for [ATP enhancer] as an “Anti-aging agent or life extending agent” and as an “Agent to protect mitochondria, ameliorate mitochondrial damage, or improve mitochondrial function”. Those publications allow us to now freely share the underlying data, which we believe represents exciting future growth opportunities.
Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine. Watanabe H, Hattori T, Kume A, Misu K, Ito T, Koike Y, Johnson TA, Kamitsuji S, Kamatani N, Sobue G. Medicine. 99(35):e21576, August 28, 2020.
Please refer to here